|Assessment Status||Rapid Review Complete|
|Drug||Insulin degludec/liraglutide (IDegLira)|
|Indication||For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.|
|Rapid review commissioned||19/09/2016|
|Rapid review completed||17/10/2016|
|Rapid review outcome||Full pharmacoeconomic assessment recommended at the submitted price.|
The HSE has approved reimbursement; July 2019.